ACTRN12615001017516
Completed
Phase 1
A Phase I/IIa Study of the Efficacy and Safety of ASN-002 Alone and in Combination with 5-Fluorouracil (5-FU) in Adult Patients with Low-Risk Nodular Basal Cell Carcinoma
Ascend Biopharmaceutical Ltd.0 sites16 target enrollmentSeptember 29, 2015
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Ascend Biopharmaceutical Ltd.
- Enrollment
- 16
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Low risk nodular basal cell carcinoma
- •2\.Biopsy of any other skin tumor
- •3\.Willingness to have injection therapy followed by surgery
- •4\.Written informed consent
Exclusion Criteria
- •1\.No or only minimal symptoms
- •2\.Known or suspected metastatic disease.
- •3\.Pregnant or Lactating females
- •4\.Clinically active or uncontrolled skin disease
- •5\.Immunocompromised or receiving immunomodulating agent
- •6\.treatment with psoralen plus UVA or UVB therapy within 6 months
- •7\.Any serious or active medical or psychiatric illness
- •8\.Recreational or therapeutic drug or alcohol use
- •9\.Taking any investigational product within 1 month of first dose of ASN\-002\.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A phase I/II study for the safety and efficacy of Panitumumab in combination with TAS-102 for patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapyunresectable advanced colorectal cancerJPRN-UMIN000019876Takeda Pharmaceutical Company Limited52
Active, not recruiting
Not Applicable
A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients - GFM-Aza intensifEUCTR2010-020341-27-FRGroupe Francophone des Myélodysplasies
Active, not recruiting
Phase 1
ot availableStaphylococcus aereus BacteremiaMedDRA version: 19.1Level: LLTClassification code 10058887Term: Staphylococcus aureus bacteremiaSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2015-003510-25-DEXBiotech USA, Inc.52
Active, not recruiting
Phase 3
A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in subjects with Transfusion-Dependent β-Thalassemia2024-516894-57-00Vertex Pharmaceuticals Inc.5
Recruiting
Phase 2
Exploratory Study of StrataXRT for Radiation Dermatitis in Breast Cancer Patients with Postoperative Radiation TherapyBreast CancerD001943JPRN-jRCT1032230451Ogita Mami50